5th March 2013 - News release

CLINICAL TRIAL OF SUBCUTANEOUS L-DOPA FOR PARKINSON'S DISEASE

NeuroDerm announced today the results of a Phase I safety and pharmacokinetic trial of ND0612. ND0612 is a novel drug formulation for the treatment of Parkinson’s Disease. NeuroDerm is a pharmaceutical company that specializes in the development of novel dermal delivery routes for CNS drugs.

ND0612 is a combination of L-dopa and carbidopa, as is Sinemet, but it is a liquid formula administered continuously sub-cutaneously (via the skin) through a patch pump. It is designed to provide steady L-dopa blood levels for the reduction of motor complications in Parkinson’s Disease.

In this double-blind, placebo controlled, dose-escalation trial in young, healthy volunteers, ND0612 was shown to be safe and tolerable in all of the tested doses. Clinically meaningful L-dopa concentrations were reached. For the first time in humans, steady state L-dopa concentrations were maintained in a practical manner both day and night, thereby enabling more even levels of L-dopa than oral forms of L-dopa. The full results of this study will be presented at a future scientific meeting. For more information go to the News release For a printable version of this article click here. For more news go to Parkinson's Disease News.